omidubicel
Phase 3- Indications
- Hematologic malignancies, Severe aplastic anemia
Company intelligence / Profile preview
Pyxis Diagnostics has developed an AI-powered computational biology platform that maps tumor–immune–stroma communication networks to predict which patients will respond to immuno-oncology therapies and to identify new drug combinations for non-responsive patients. The technology enables identification of predictive biomarkers and potential new therapeutic targets by comparing cellular network patterns between responders and nonresponders. No clinical trial results are reported as the company focuses on diagnostic/prognostic tools rather than therapeutics[1][2][4][6].
5 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pyxis Diagnostics.